en · de · es · fr · pt
assay-notes.peptides6088.com › Wiki › Molecular Identity Of Thymosin Alpha-1 — Questions and Answers

Molecular Identity Of Thymosin Alpha-1 — Questions and Answers

By Editorial Desk · published 2026-04-14 · last reviewed 2026-05-13 · Wiki

This is a working overview of reverse-phase HPLC, written for readers who want more than a one-paragraph summary but less than a textbook.

Reviewed 2026-05-13. Anything still debated is marked as such rather than presented as settled.

Molecular Identity Of Thymosin Alpha-1

Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.

Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.

Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.

Analytical Methods and Storage Stability

Quality control for thymosin alpha-1 focuses on identity, purity, and potency. Identity is confirmed by mass spectrometry and amino acid analysis, while purity is assessed by chromatography with limits on related substances and residual solvents. Potency assays may use cell-based immune readouts, but these are not standardized across laboratories. Regulatory status differs by jurisdiction; no product is approved in the United States for clinical use, whereas some other countries register injectable forms for specific indications.

Quantifying thymosin alpha-1 in a sample usually relies on reverse-phase high-performance liquid chromatography. The peptide lacks strong chromophores, so detection often occurs at 214 nm, where the peptide backbone absorbs. Mass spectrometry provides confirmatory identification and can detect sequence variants or truncations. Immunoassays have been used in biological matrices, but they may cross-react with related fragments. For purity assessment, chromatographic peak area gives the main component percentage, while mass accuracy verifies molecular identity.

The lyophilized peptide is generally stable for extended periods when kept cold and dry. Once dissolved, aqueous solutions are less stable; hydrolysis, oxidation, and aggregation can degrade the material. Storage at -20 °C or lower slows these processes. Repeated freeze-thaw cycles are best avoided because they can promote aggregation. The exact shelf life depends on formulation, pH, and concentration, so stability studies are typically performed for each specific product.

Thymosin-alpha-1 at a glance

PropertyValueNotes
ClassSynthetic peptide28 residues; not a small-molecule compound
Molecular massAbout 3,106 DaMonoisotopic mass of the unmodified chain
N-terminal groupAcetylated serinePresent in both native and synthetic forms
Secondary structureDisulfide-constrained loopOne bridge between two cysteine residues
Typical sourceSolid-phase synthesisEarly isolates came from bovine thymus extracts

Molecular Background and Immune Action

Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.

Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.

Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.

Related pages on this site

Background and Biological Role

Thymosin alpha-1 is a short peptide of 28 amino acid residues first described in the 1970s as a component of thymic extracts. Its N-terminal residue carries an acetyl group, and the sequence is highly conserved across mammalian species. The peptide is not encoded as a standalone gene product; it is released by proteolytic cleavage from the N-terminus of prothymosin alpha, a larger acidic nuclear protein. That precursor relationship places it within a broader family of thymic and immune-associated peptides that have been studied for decades.

The activity of this peptide is generally described as immunomodulatory rather than directly antimicrobial. Experimental work links it to signaling through certain Toll-like receptors on dendritic cells and to downstream maturation of antigen-presenting cells. Reported effects include expansion of T cell subsets, shifts in cytokine profiles, and increased natural killer cell activity. These observations come largely from cell culture and animal models, and the precise receptor-level events in humans remain incompletely characterized.

Molecular Background and Identity

Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.

Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.

Storage Handling And Laboratory Analysis

Identity and purity are usually checked by reverse-phase high-performance liquid chromatography, which separates the intact chain from truncated products, together with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion and amino acid analysis add sequence-level evidence. Release testing also covers water content, residual solvents, and counter-ions, all of which influence measured mass and stability. Related-peptide limits are commonly expressed as a percentage of total peak area, with individual unspecified impurities held below a lower threshold.

The lyophilized peptide is a white to off-white powder that dissolves freely in water and in aqueous buffers near neutral pH. Because the molecule carries a net negative charge under physiological conditions, saline and phosphate solutions are the usual vehicles, while strongly acidic media are avoided. Stock solutions are commonly divided into small aliquots so that repeated freezing and thawing can be limited, since cycling may encourage aggregation. Solubility in organic solvents is poor and those solvents are seldom used as primary diluents.

Supporting material

=== On Mars === Thiophene derivatives have been detected at nanomole levels in 3.5 billions year old Martian soil sediments (Murray Formation, Pahrump Hills) by the rover Curiosity at Gale crater (Mars) between 2012 and 2017.

=== Background === Influenced by strategic analyses such as the 1976 Team B report—which argued U.S. intelligence had vastly underestimated Soviet threats—and ideas of the Citizens' Advisory Council on National Space Policy, President Ronald Reagan announced the Strategic Defense Initiative (SDI) in 1983. It proposed a space-based global missile defense constellation intended to render nuclear weapons "impotent and obsolete." The program immediately faced challenges, with concerns by Congress, including prominent senators Sam Nunn and Joe Biden, over its apparent violation of the Anti-Ballistic Missile Treaty, questionable technical feasibility, spiraling launch costs, poor cost-exchange ratio, and destabilizing impact on arms control. By the 1990s, SDI was formally restructured into the Ballistic Missile Defense Organization, pivoting from space-based platforms to more proven ground- and sea-based systems. U.S. missile defense policy continued to evolve, with the 1999 National Missile Defense Act mandating a system to defend against limited ballistic missile attacks. Following a later Team B report's recommendation, President George W. Bush withdrew the U.S. from the ABM Treaty in 2001. The Obama administration's 2010 Review shifted focus from a homeland-centered shield to more flexible and cooperative regional defenses, limiting the space component to sensing and tracking. This was adjusted by the Trump administration's 2019 Review, expanding scope from rogue states such as North Korea, to include advanced hypersonic threats from "competitors" like Russia and China.

In the cytosol, acetyl-CoA carboxylase (ACC) generates malonyl-CoA from acetyl-CoA and CO2 and is responsible for the majority of the cellular malonyl-CoA pool. The amount of malonyl-CoA in the cytosol is tightly regulated by the opposing activities of ACC and malonyl-CoA decarboxylase (MCD), which catalyzes the reverse reaction to produce acetyl-CoA and CO2. Cytosolic malonyl-CoA plays a key role in regulating fatty acid metabolism. Although malonyl-CoA itself cannot enter mitochondria, malonate produced through non-enzymatic hydrolysis of cytosolic malonyl-CoA may cross membranes and contribute to the mitochondrial malonyl-CoA pool. In mitochondria, the malonyl-CoA pool is generated by acyl-CoA synthetase family member 3 (ACSF3), which catalyzes the thioesterification of malonate and CoA, and by a mitochondrial isoform of acetyl-CoA carboxylase 1 (mtACC1), which produces malonyl-CoA through the carboxylation of acetyl-CoA and CO2. Complementing these synthetic activities, MCD likeweise operates in mitochondria, where it converts malonyl-CoA back to acetyl-CoA and CO2. Mitochondrial malonyl‑CoA is essential for local protein malonylation as well as for mitochondrial fatty acid synthesis (mtFAS). In the nucleus, malonyl-CoA is synthesized by ACC1, which is mainly cytoplasmic, suggesting a local and possibly unconventional function. The extent of malonylation increases with malonyl‑CoA availability particularly under conditions such as metabolic stress or enzyme deficiencies, for example malonyl‑CoA decarboxylase deficiency.

Main sections: §§ Signaling after internalisation​ and Conformational states The persistent signaling that is present after internalisation could be the reason for ineffectivity of common KOR antagonists given that they work on receptor's outer membrane. Antagonists also tend to preserves conformation states; in this case presumably "alternative state" due to the endogenous bias for the β-arrestin signaling during stress responses.

== Administration of ACAM2000 == The ACAM2000 vaccine is produced from the vaccinia virus, which is sufficiently closely related to smallpox to provide immunity, but the ACAM2000 vaccine cannot cause smallpox because it does not contain the smallpox virus. Other vaccines containing live viruses include measles, mumps, rubella, polio and chickenpox. The vaccine is administered using a bifurcated stainless steel needle. The needle is dipped into the vaccine solution and used to prick the skin several times in the upper arm. The vaccinia virus will begin to grow at the injection site. It will cause a localized infection, with a red itchy sore produced at the vaccination site within three to four days. If the infection occurs, that is an indication that the vaccine was successful. Ultimately, the sore turns into a blister and then dries up. A scab forms and then falls off in the third week, leaving a small scar behind.

Sources: en.wikipedia.org

Supporting material

== Bibliography == Grigoroff, Stamen (1905). "Etude sur le lait fermenté comestible : le 'Kissélo-mléko' de Bulgarie". Revue Médicale de la Suisse Romande (in French). Genève: Libraires-Éditeurs. Librairie de L'Université. OCLC 717162535. Balows A, Truper HG, Dworkin M, Harder W, Schleifer KH (1992). "70". The Prokaryotes: A Handbook on the Biology of Bacteria (2nd ed.). New York: Springer-Verlag. p. 1547. ISBN 978-3-540-97258-7. OCLC 23767548.

The degree of strictness of border controls varies across countries and borders. In some countries, controls may be targeted at the traveller's religion, ethnicity, nationality, or countries visited. Others may need to ensure the traveller has paid the appropriate fees for their visas and has future travel planned outside the country. Yet others may concentrate on the contents of the traveller's baggage and imported goods to ensure nothing is being carried that might pose a biosecurity risk to the country.

phosphate backbone Also phosphodiester backbone, sugar–phosphate backbone, and phosphate–sugar backbone. The linear chain of alternating phosphate and sugar compounds that results from the linking of consecutive nucleotides in the same strand of a nucleic acid molecule, and which serves as the structural framework of the nucleic acid. Each individual strand is held together by a repeating series of phosphodiester bonds connecting each phosphate group to the ribose or deoxyribose sugars of two adjacent nucleotides. These bonds are created by ligases and broken by nucleases.

== Structure == These proteins are characterized by having three disulfide bonds in a characteristic motif. Some family members have an additional disulfide bond also in a conserved location. All of these proteins have a helical segment (corresponding to B chain in insulin) followed by a variable-length chain, followed by a domain (A chain in insulin) with two helices pinned against each other via a disulfide bond. These two regions are linked by two or three disulfide bonds. Amongst the different proteins in the family, very little of the sequence is conserved except for the disulfide bonds. The variable-length chains may exhibit large inter-species variation even when the remainder of the sequence is highly conserved; and as is in the case of insulin, sometimes the variable length chain is cleaved out by secretory endoproteases, leaving a two-chain protein held together by disulfide bonds.

Sources: en.wikipedia.org

Notes from published material

external causes: these include the Six Excesses and "Pestilential Qi". internal causes: the "Seven Affects" (七情; qī qíng, sometimes also translated as "Seven Emotions") – joy, anger, brooding, sorrow, fear, fright and grief. These are believed to be able to cause damage to the functions of the zàng-fú, especially of the Liver. non-external-non-internal causes: dietary irregularities (especially: too much raw, cold, spicy, fatty or sweet food; voracious eating; too much alcohol), fatigue, sexual intemperance, trauma, and parasites (虫; chóng).

== External links == Target+Peptide at the U.S. National Library of Medicine Medical Subject Headings (MeSH) SPdb (Signal Peptide DataBase) Archived 2016-01-22 at the Wayback Machine Prediction methods: SignalP — predicts the presence and location of signal peptide cleavage sites in amino acid sequences from all domains of organisms. PHOBIUS - combined transmembrane topology and signal peptide predictor

Prior to that, at a rally in Alor Setar, he had similarly urged Anwar to step down, citing mismanagement of national wealth and poor governance. In December 2025, Mahathir lodged a police report accusing Anwar of economic sabotage and undermining Malaysia's sovereignty over the Malaysia–United States Agreement on Reciprocal Trade (ART), an agreement that later sparked public controversy over provisions seen by critics as obliging Malaysia to align with US sanctions, compromise regulatory autonomy, and weaken the country's long-standing policy of non-alignment. In early January 2026, Mahathir was admitted to the National Heart Institute (IJN) for observation after he fell at his residence and was taken to hospital by ambulance. Hospital officials later confirmed that he had sustained a fracture to his right hip and remained in stable condition while receiving treatment. According to his son, Mukhriz Mahathir, medical specialists advised that he was not suitable for hip replacement surgery due to age-related risks, and that a non-surgical recovery approach would be adopted. Mahathir's hospitalisation attracted significant domestic and international attention, with Turkish President Recep Tayyip Erdoğan conveying his concern and well wishes during a meeting with Prime Minister Anwar Ibrahim while the latter was on an official visit to Turkey. On 29 September, the day after his wife Siti Hasmah died, Mahathir was hospitalized at the National Heart Institute in Kuala Lumpur.

The modifications described here cover alterations to the ring structure donated by the fentanyl precursor 4-ANPP. Although another series covered substitutions of hydrogen atoms on the original carbon ring structure, sometimes called functional group additions, this series focuses on the three main modifications to the phenethyl moiety. The first modifications is the removal of the phenethyl moeity from the piperidinyl nitrogen, depicted here as hydrolysis yielding phenethanol. This changes the parent skeletal name to norfentanyl. The second and third modifications are the removal and addition of a methylene moiety internally in the ethyl chain within the greater phenethyl moiety. The removal of a methylene, which shortens the chain by one carbon length, creates the benzylfentanyl structure. The addition of a methylene, which lengthens the chain by one length, creates homofentanyl.

The use of a gradually building rhythmic motif. These include "The Devil's Triangle" (an adaptation and variation on the Gustav Holst piece Mars played by the original King Crimson, based on a complex pulse in 54 time over which a skirling melody is played on a Mellotron), 1973's "The Talking Drum" (from Larks' Tongues in Aspic), 1984's "Industry" (from Three of a Perfect Pair) and 2003's "Dangerous Curves" (from The Power to Believe). An instrumental piece (often embedded as a break in a song) in which the band played an ensemble passage of considerable rhythmic and polyrhythmic complexity. An early example is the band's initial signature tune "21st Century Schizoid Man", but the "Larks' Tongues in Aspic" series of compositions (as well as pieces of similar intent such as "THRAK" and "Level Five") went deeper into polyrhythmic complexity, delving into rhythms that wander into and out of general synchronisation with each other, but with all 'finishing' together through polyrhythmic synchronisation. These polyrhythms were particularly abundant in the band's 1980s work, which contained gamelan-like rhythmic layers and continual overlaid staccato patterns in counterpoint. The composition of difficult solo passages for individual instruments, such as the guitar break on "Fracture" on Starless and Bible Black. The juxtaposition of ornate tunes and ballads with unusual, often dissonant noises (such as "Cirkus" from Lizard, "Ladies of the Road" from Islands and "Eyes Wide Open" from The Power to Believe). The use of improvisation. Ascending note structure (e.g.

Sources: en.wikipedia.org

Frequently asked questions

Is this peptide found naturally in the body?

Its sequence corresponds to the amino-terminal portion of prothymosin alpha, a larger protein present in many cell types. The isolated 28-residue peptide is a fragment of that protein rather than a separately encoded molecule, and laboratory material is produced by synthesis.

Why is the disulfide bridge important?

The single bridge between two cysteine residues holds the chain in a folded loop that influences its shape and its behavior in solution. Loss of the bridge through reduction or oxidation shifts chromatographic retention and is tracked during stability work.

How does it differ from other thymic peptides?

It is a defined 28-residue sequence derived from a larger precursor, whereas many other thymic preparations are mixtures of several polypeptides. Its acetylated amino terminus and single disulfide bridge distinguish it chemically from unrelated thymic extracts.

How is thymosin alpha-1 measured in a laboratory?

Reverse-phase HPLC with ultraviolet detection at 214 nm is common. Mass spectrometry is used to confirm molecular identity and detect modifications. Immunoassays exist but may not distinguish the intact peptide from fragments.

Network